Theracryf PLC (AIM:TCF) delivered a compelling investor presentation highlighting strong operational progress, robust financial management, and a renewed strategic focus on its lead Orexin-1 (OX1) antagonist targeting substance use and behavioural disorders. The company’s key asset, acquired via Kronos Therapeutics, demonstrates industry-leading selectivity and pharmacokinetics - outperforming other clinical-stage peers - with potential applications across addiction, binge eating, and broader CNS indications. With global patents secured through 2038–2039 in the US and Europe and filings underway in Asia and Latin America, the intellectual property portfolio provides a strong foundation for future licensing or partnerships with Big Pharma. Backed by a £4.25m raise - one of the largest on AIM in 2024 - Theracryf is fully funded to reach a major inflexion point: IND/IMPD-enabling studies and clinic readiness by late 2025. The company reported a 40% reduction in operating loss, doubled its cash position to £4.1m, and ranks in the top 20% of European biotechs for cash runway, now extending into late 2026. Management emphasised that while near-term revenue from product sales is not expected, monetisation will occur via strategic out-licensing or early-stage partnerships. Additional pipeline assets include SFX-01, advancing under an EU grant for glioblastoma, and a dopamine reuptake inhibitor programme in fatigue and narcolepsy. With a strengthened board, tight cost control, and a clear route to clinic, Theracryf presents an attractive, de-risked investment case with significant upside potential in the £60bn+ CNS and addiction therapeutics market.

Trellus Health’s FY2024 investor update highlights strong commercial momentum, operational discipline, and a differentiated growth strategy anchored in its proprietary resilience platform, Trellis Elevate. Purpose-built to transform chronic condition management, the platform enhances patient engagement, adherence, and outcomes by bridging the critical gap between mental and physical health. In 2024, Trellis launched its first large-scale U.S. health plan pilot, signed strategic licensing deals with Pfizer and AstraZeneca, and secured a commercial agreement with Johnson & Johnson for its inflammatory bowel disease therapies. Post-period highlights include renewed licensing deals, platform expansion, and global readiness with content translated into 57 languages. Year-to-date contracted revenue reached $340k, and disciplined cost management reduced the company’s monthly cash burn by 22%, extending its cash runway into October 2025. The company reported a $7.2M adjusted EBITDA loss, in line with expectations, and emphasized its scalable, asset-light revenue model with upfront implementation and monthly management fees. Trellis is actively targeting revenue growth across pharma, health plans, and clinical trials by embedding its resilience methodology into patient support programs and trial recruitment and retention. Backed by published two-year outcome data demonstrating sustained reductions in ED visits and hospitalisations, Trellis Health is uniquely positioned to drive value across the healthcare ecosystem. With a strong order pipeline and strategic vertical diversification, the company is entering a phase of scalable, predictable revenue growth.

Chesterfield Special Cylinders Holdings PLC (formerly Pressure Technologies) delivered its FY25 interim results, highlighting solid strategic momentum across defence, hydrogen, and integrity management sectors. While revenue of £5.4m reflected the phasing of new-build contracts and delayed UK naval deployments, robust H1 order intake—£10m in defence and £3m in hydrogen—supports full-year revenue forecast to more than double H1 and a return to adjusted EBITDA profitability. Overseas defence orders surged 67%, including contracts with the US, Canadian, Spanish, and Australian navies, reinforcing the company’s position as a key supplier of safety-critical pressure systems. In hydrogen, the company secured its first large-scale UK contract for the BP Aberdeen hub and expanded into composite cylinder systems via a new European partnership. Hydrogen order intake more than tripled vs H1 FY24, supporting Chesterfield’s 2028 target of hydrogen contributing 30% of total revenue. Integrity management services also posted record H1 growth, with revenue up 17% and full-year performance expected to set new highs. With over 95% of H2 revenue already covered, low capex needs, and growing demand across its core markets, Chesterfield remains confident in achieving its FY25 targets and delivering on its 2028 strategic plan. Key financial keywords: investor update, financial results, strategic growth, order book, adjusted EBITDA, revenue, hydrogen storage, defence contracts, lifecycle services, margins, profitability outlook.

Refuels N.V reported a milestone Q4 with its first profitable quarter since listing, supported by £4.2m EBITDA and £3.4m pre-tax profit, underpinned by rising truck adoption, efficient biomethane sourcing, and improved RTFC margins. Operating a fast-growing UK network of 16 grid-connected refuelling stations and 10+ mobile refuelling units, Refuels now serves over 2,000 HGVs daily—saving 216,000 tonnes of CO₂e in 2024. The company is targeting a doubling of refuelling capacity in three years, backed by a simplified corporate structure and anticipated debt facility following its transformational integration with Foresight. The arrival of 6x2 CNG trucks from Scania and Iveco marks a major market unlock, with pre-orders already exceeding expectations. Refuels is fully sourced for 2025 biomethane supply, with favourable RTFC pricing (23p–26p) driving margin recovery towards historical 30% levels. Gross profit surged to £17m (vs £2.3m FY23), and station-level EBITDA hit £7m, demonstrating economies of scale and robust infrastructure returns with typical station payback under five years. As Europe ramps up biomethane investment, Refuels is well-positioned to lead HGV decarbonisation through cost-competitive, renewable, and locally sourced fuel. With expanding customer demand, a clear earnings visibility, and a scalable low-carbon infrastructure platform, Refuels offers a compelling growth and ESG-aligned investment proposition.

Thor Explorations Ltd. (LSE:THX) delivered a robust Q1 2025 investor update, highlighting record financial results, growing cash flow, and strategic exploration progress across its diversified West African gold portfolio. The Company reported quarterly gold production of 22,700 ounces and revenue of $64.1 million, maintaining industry-leading all-in sustaining costs below $1,000/oz. Net income surged to over $34 million, with net cash doubling to $24.5 million. Thor reaffirmed full-year guidance of 85,000–95,000 ounces and announced its maiden quarterly dividend of C$0.0125 per share, supported by a resilient balance sheet and high-margin unhedged exposure to elevated gold prices.

Flagship Segilola Gold Mine in Nigeria continues to generate strong operational cash flow, with ongoing drilling beneath the pit confirming high-grade mineralization and underpinning near-term mine life extension. In Senegal, aggressive drilling at the Douta Project's Baraka prospect has deferred the PFS to incorporate new high-grade oxide discoveries, targeting a resource upgrade and feasibility study by H2 2025. In Côte d’Ivoire, Thor is advancing its Guiglo and Marahui exploration licenses, where recent soil sampling and high-grade rock chip assays over a 5km trend point to significant discovery potential. The company is also progressing early-stage lithium and satellite gold targets near Segilola, aiming to integrate them into its long-term production pipeline.

With no outstanding warrants, increasing institutional interest, a C$450M+ market cap, and a fully funded exploration programme across Nigeria, Senegal, and Côte d’Ivoire, Thor is well-positioned to deliver sustained shareholder returns and long-term value through organic growth, operational efficiency, and disciplined capital allocation.

EasyJet PLC’s latest investor update highlights steady progress in executing its FY25 growth strategy, underpinned by resilient customer demand, expanding EasyJet Holidays, and a clear path to sustainable margin expansion. With 42% of peak summer seats already sold—2% ahead year-on-year—and winter losses narrowed after adjusting for Easter timing, trading momentum remains strong. EasyJet Holidays delivered £43m winter profit and is on track to exceed its £250m medium-term profit before tax target. The Group continues to modernise its fleet, replacing ageing A319 aircraft with more efficient A320neo and A321neo models, expected to boost productivity and reduce unit costs by £3 per seat by FY28. The book value of EasyJet’s owned fleet is set to rise 60% over this period, reinforcing its robust £4.6bn investment-grade balance sheet. Strategic expansion at slot-constrained airports - including new bases in Milan, Rome, Southend, and Newcastle - supports EasyJet’s vision of building Europe’s best short-haul network. Efficiency gains are also being driven by in-house maintenance capabilities and AI-driven operational planning tools. In-flight retail revenues rose 15% per seat, with further upside targeted through product personalization and brand partnerships. Management reaffirmed confidence in delivering its medium-term targets, including over £1bn profit before tax, high-teens ROCE, and 35% capacity CAGR. Dividends have resumed, with a 20% payout of post-tax profits reflecting EasyJet’s commitment to shareholder returns.

Hollywood Bowl Group delivered a record first-half performance for FY25, reporting revenue growth of 8.4% to £129.2 million and adjusted EBITDA of £38.8 million, up 8.8% despite inflationary pressures and weather-related headwinds. UK like-for-like revenue grew 1.5%, supported by 6.3% growth in spend per game. In Canada, revenue rose to CAD $38 million, driven by new centre openings and a doubling of supply-partner Striker’s revenue. The Group opened five new centres—three in the UK and two in Canada—while progressing its refurbishment programme targeting 33% ROI. Net cash stood at £22.7 million post a £10 million share buyback, with a newly secured £25 million revolving credit facility undrawn. Statutory profit before tax was £28.3 million, with EPS of 12p. The Board declared an interim dividend of 4.1p, in line with a revised 34% payout policy of the prior year’s total dividend. Hollywood Bowl reaffirmed its capital allocation strategy focused on organic growth, disciplined investment, and shareholder returns. In Canada, EBITDA has grown from CAD $2.8m to CAD $9.5m since acquisition, with a clear roadmap for growth through new site formats and refurbishments. With a robust pipeline, leading market position, and proven resilience, the Group is well positioned to deliver long-term revenue and EBITDA growth across both markets.

Braemar plc delivered a resilient FY25 performance, underpinned by a robust diversification strategy and disciplined cost management. Despite a 7% decline in revenue to £141.9 million, driven by softer tanker and dry cargo rates in H2, underlying operating profit margin was maintained at 12%, reflecting tight cost control and operational efficiencies. The Group's investment advisory division saw strong 18% growth, highlighting the effectiveness of its broader revenue mix. Net debt of £2.5 million at year-end was quickly reversed in line with Braemar's typical working capital cycle. A solid forward order book of $82.2 million underscores revenue visibility, while total shareholder returns were maintained through a £2 million share buyback and a revised final dividend of 2.5p. Looking ahead, Braemar has launched a refreshed strategic framework targeting £200m in revenue by FY30 and a 15% EBITDA margin, supported by continued investments in talent, digital infrastructure, and M&A opportunities. Regulatory tailwinds, an ageing global fleet, and increasing demand for decarbonised shipping solutions present significant growth opportunities. With global presence across 18 offices and a focus on operational excellence, Braemar remains well positioned to capitalise on shipping market dynamics, enhance margins, and deliver long-term shareholder value.

Impax Asset Management’s interim results for the six months to 31 March 2025 reflect a business navigating short-term headwinds while strengthening its long-term strategic position. Despite a challenging first half marked by continued outflows—most notably the loss of the St. James’s Place mandate—Impax reports a significant turnaround in investment performance, with over 70% of AUM outperforming benchmarks year-to-date. Revenue and EBITDA declined modestly, in line with reduced assets under management, while a disciplined cost reduction programme delivered £11m in run-rate savings, protecting margins (26.8%) amid falling income. Impax maintained a strong balance sheet, ending the period with £63.1m in capital surplus, and reaffirmed its commitment to shareholders through a rebased dividend of 4.0p and a £10m share buyback. Strategic growth priorities include scaling its fixed income offering—bolstered by the acquisition of Sky Harbor—and expanding private equity exposure in European renewable energy. Distribution capabilities were enhanced in Scandinavia, Canada, and emerging markets. With improving market conditions, strong institutional interest, and a return to benchmark outperformance, Impax expects net inflows to resume in FY2026. The firm remains focused on sustainable investing, EBITDA growth, and disciplined capital allocation, positioning itself as a global leader in the transition to a more sustainable economy.